THE ALL -IN -ONE REGENERATIVE BIOLOGIC
OUTPERFORMS PRP, GFC, PGFC, & PLATELET LYSATE
5X Growth Factors vs. Standard PRP
IL-1Ra - Pain & Anti Inflammation Block
Cell Free - Minimal Immune Response
AN ADVANCING MARKETPLACE
Orthonovus is primed to Lead In Evidence Based Regeneartive Medicine
The regenerative marketplace is shifting toward an evidence based market and OrthoNovus is prepared to be a leader in this shift. Our process is standardized and we produce consistent, reproducible results. Clinical Certainty is where our roadmap leads.
Regenerative Biotech Platform
Standardized Activation of Autologous Growth Factors
OrthoNovus utilizes our propreietary platform to activate growth factors that trigger cellular repair mechanisms and modulates pain and inflammation in a novel way.
Our platform provides clinicians across multiple disciplines to use regenerative biotechnology in ways that provide superior tissue regeneration in a standardized potency that is consistent in every dose.
5 REASONS AGF OUTPERFORMS EVERY ALTERNATIVE
1
2
3
4
5
All-in-One Biologic Solution
Superior Pain & Inflammation Control
Pre-Activated+Immediate Action
No Invasive Harvesting Requried
Consistent, Reproducible Results
AGF combines IL-1Ra, anti-inflammatory cytokines, and pre-activated growth factors in a single injectible-eliminating multiple seperate biologic therapies
Il-1Ra Blocks pain pathways more effectively than PRP, GFC or PGFC. Agf also modulates TNF-a and neuroinflammation-mechanisms PRP cannot address
Unlike PRP or GFC which wait for platelet degranulation, AGF delivers pre-activated growth factors for faster onset, angiogenesis and ECM remodeling.
BMAC needs bone marrow aspiration, SVF requires liposuction. AGF needs only a single blood draw-minimally invasive, standardised, and repeatable.
PRP, GFC, and BMAC outcomes are donor-dependent. AGF is prepared to standardised concentrations-delivering predictable outcomes every time
The AGF Advantage
One Therapy.
Pain - Inflammation - Regeneration
Clinical Applications
Strategic deployment of the autologous Activated Growth Factor platform across critical clinical verticals. Engineered to deliver biological precision and standardized outcomes where other regenerative therapies lack evidence-based consistency.
Orthopedics
- Osteoarthritis (Knee, Hip, Shoulder)
- Tendinopathy & Ligament Injuries
- Rotator Cuff Partial Tears
- Chronic Back & Joint Pain
- Post-Surgical Joint Recovery
- Cartilage Degeneration
Sports Medicine
- Muscle and Tendon Strains
- Post-Surgical Recovery
- Overuse Injuries
- Return-to-Play Optimisation
- Acute Ligament Sprains
- Athletic Performance Tissue Support
About OrthoNovus
OrthoNovus is dedicated to revolutionizing clinical recovery through the precision engineering of autologous growth factor concentration systems.
At the intersection of biotechnology innovation and clinical efficacy, OrthoNovus develops sophisticated platforms designed for the next generation of regenerative medicine. Our focus remains steadfast on autologous activation—leveraging the patient’s unique biological profile to optimize repair mechanisms with institutional precision.
By providing clinicians with a robust framework for regenerative protocols, we ensure that every application is data-driven and outcomes-oriented. Our commitment to scientific rigor establishes OrthoNovus as a vital partner for institutional investors and healthcare providers seeking to scale evidence-based biotech solutions across multiple verticals.
Leadership Team
Matt Glass D. C.
CEO
VS Biologics
Chief Science Officers
Patrick Struebi
CFO
Get in Touch
We invite inquiries, partnership discussions, and mailing list sign-ups from clinicians, investors, and strategic partners to help drive regenerative biological precision forward.